drugset / Trial / NCT02310646

Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris

NCT02310646

Phase 3 Completed 219 enrolled LEO Pharma
RandomizedCrossoverOpen-labelOther

Summary

To gather insight on how product attributes affect usability by investigating the factors that are thought to influence patient preference to topical anti-psoriatic treatments.

Timeline

Start
2015-01
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Betamethasone Other / unclassified Topical
Comparator Calcipotriol Small molecule Topical

Indications